+86-27-65522453 sales@sun-shinechem.com

CUDC-101

Catalog No.: 91303
Cas No.: 1012054-59-9
Purity : 98% 
91303 - CUDC-101 | CAS 1012054-59-9

Catalog number : 91303

CAS number : 1012054-59-9

Molecular Formula : C24H26N4O4 

Molecular Weight : 434.49 

Iupac Chemical Name : 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide 

Smile : O=C(NO)CCCCCCOC1=CC2=C(NC3=CC=CC(C#C)=C3)N=CN=C2C=C1OC

InChiKey : PLIVFNIUGLLCEK-UHFFFAOYSA-N

PackagingPriceAvailabilityPurityEstimated Shipping Time
BulkEnquiryEnquiry
Request Bulk Quote Download MSDSTel:+86-27-65522453 | Email:sales@sun-shinechem.com
SynonymsCUDC-101;CUDC 101;CUDC101. 
Molecular FormulaC24H26N4O4 
Molecular Weight434.49 
Appearanceoff-white solid 
Purity98% 
SolubilitySoluble in DMSO 
Storage3 years -20ºCpowder 6 months-80ºCin solvent 
Shipping ConditionShipped under ambient temperature 
SmileO=C(NO)CCCCCCOC1=CC2=C(NC3=CC=CC(C#C)=C3)N=CN=C2C=C1OC
InChiKeyPLIVFNIUGLLCEK-UHFFFAOYSA-N
InChiInChI=1S/C24H26N4O4/c1-3-17-9-8-10-18(13-17)27-24-19-14-22(21(31-2)15-20(19)25-16-26-24)32-12-7-5-4-6-11-23(29)28-30/h1,8-10,13-16,30H,4-7,11-12H2,2H3,(H,28,29)(H,25,26,27)
Coming soon.

CUDC-101 is a novel, small-molecule, anticancer agent targeting histone deacetylase (HDAC), EGF receptor (EGFR), and HER2. It is currently in phase I clinical development in patients with solid tumors. CUDC-101 has potent antiproliferative and proapoptotic activity in cultured tumor cells and in vivo xenograft models. It has been shown that cancer cells that have acquired resistance to single-target EGFR inhibitors through upregulation of AXL or loss of E-cadherin remain sensitive to CUDC-101, which inhibits MET- and AXL-mediated signaling, restores E-cadherin expression, and reduces cell migration. CUDC-101 also efficiently inhibited the proliferation of MET-overexpressing non-small cell lung cancer and gastric cancer cell lines and inhibited the migration and invasion of invasive tumor cells. Taken together, these results suggest that coupling HDAC and HER2 inhibitory activities to an EGFR inhibitor may potentially be effective in overcoming drug resistance and preventing cancer cell migration.

 

1012054-59-9 - Request Bulk Quote

×
1012054-59-9 - Request Bulk Quote
Change